{"id":"NCT01498653","sponsor":"GlaxoSmithKline","briefTitle":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry","officialTitle":"A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-12-23","resultsPosted":"2013-12-20","lastUpdate":"2017-01-09"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"GW685698/GW642444","otherNames":[]},{"type":"DRUG","name":"CCI18781","otherNames":[]}],"arms":[{"label":"FF/VI 200/25mcg once daily","type":"EXPERIMENTAL"},{"label":"Fluticasone propionate 500mcg twice daily","type":"ACTIVE_COMPARATOR"}],"summary":"A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy","primaryOutcome":{"measure":"Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period","timeFrame":"Baseline and Weeks 1-12 (up to Day 84)","effectByArm":[{"arm":"Fluticasone Furoate/Vilanterol 200/25 µg Once Daily","deltaMin":39.1,"sd":3.01},{"arm":"Fluticasone Propionate 500 µg Twice Daily (BID)","deltaMin":10.5,"sd":3.03}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["China","Philippines","South Korea"]},"refs":{"pmids":["25524507"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":155},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Rhinitis allergic"]}}